BiotechTube
Vivace Therapeutics

Vivace Therapeutics

San Francisco, United States· Est.
vivacetherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Vivace Therapeutics is a private, clinical-stage biotechnology company pioneering novel small molecule inhibitors targeting the Hippo-YAP pathway for cancer treatment. Its lead candidate, VT3989, is in Phase 1/2 trials for refractory mesothelioma and other solid tumors, representing a first-in-class approach. The company is backed by a seasoned management team and prominent life science investors, positioning it to address a significant unmet need in oncology, particularly in cancers driven by NF2 mutations and YAP hyperactivity.

Oncology

Technology Platform

Small molecule drug discovery platform focused on inhibiting the YAP-TEAD transcription complex within the Hippo signaling pathway, primarily via targeting TEAD auto-palmitoylation.

Opportunities

VT3989 addresses a high unmet need in refractory mesothelioma and NF2-mutant tumors, with no approved therapies targeting the Hippo-YAP driver.
Successful proof-of-concept could unlock development in a wide range of major solid tumors where YAP drives resistance and poor outcomes.
The platform also has potential for expansion into large non-oncology markets like fibrotic diseases.

Risk Factors

The primary risk is clinical validation of a first-in-class mechanism; the safety and efficacy of inhibiting YAP-TEAD in humans is unproven.
The company faces significant competition from other biotechs pursuing the same pathway.
As a pre-revenue private company, it remains dependent on financing to reach key milestones.

Competitive Landscape

Vivace is among the front-runners in developing YAP-TEAD inhibitors, a nascent but competitive field. Companies like IDEAYA Biosciences (with a TEAD inhibitor in Phase 1) and others are pursuing similar strategies. Competitive advantage hinges on clinical differentiation, potency, safety profile, and speed of development.

More companies in Biologics / Biosimilars →More companies in United States →